Posted by Michael Wonder on 17 May 2022
MHRA marketing authorisation granted for Eli Lilly’s Verzenios as early breast cancer treatment
17 May 2022 - Authorisation of the treatment is based on results from the Phase 3 trial.
Eli Lilly’s Verzenios (abemaciclib) has received a marketing authorisation from the MHRA, in combination with endocrine therapy for the adjuvant treatment of patients with hormone receptor positive, HER2 negative, high risk node positive early breast cancer.
